29.03.2022 - 01.04.2022Hotel Novotel London West, International Ctre, 1 Shortlands, Hammersmith, W6 8DR London, United Kingdom
Time: 08:00 to 16:00
Temas de la conferencia With the approvals of Zynlonta and Tivdak within the last 12 months there are now 11 commercially available ADCs on the market. Furthermore, recent Enhertu and Polivy data suggests that ADCs could be soon be used as earlier line treatments to improve patient outcomes sooner. Undoubtedly, the momentum and inspiration that ADCs and ADC developers are gathering means that it's an incredibly exciting time for the entire community.